Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Canaccord Genuity Group

Equities researchers at Canaccord Genuity Group began coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm set a “buy” rating and a $10.00 price target on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 80.51% from the company’s previous close.

Several other equities analysts have also commented on CMPX. Wall Street Zen upgraded shares of Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Lifesci Capital began coverage on Compass Therapeutics in a research report on Monday, October 6th. They issued an “outperform” rating and a $10.00 target price on the stock. Compass Point set a $10.00 price target on Compass Therapeutics in a research report on Monday, October 6th. Citigroup assumed coverage on Compass Therapeutics in a research note on Wednesday. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald began coverage on Compass Therapeutics in a research note on Wednesday. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Compass Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Stock Up 4.9%

Shares of Compass Therapeutics stock opened at $5.54 on Wednesday. Compass Therapeutics has a 52 week low of $1.33 and a 52 week high of $5.86. The business’s fifty day simple moving average is $4.37 and its 200-day simple moving average is $3.39. The firm has a market cap of $985.34 million, a PE ratio of -12.31 and a beta of 1.44.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. As a group, equities analysts expect that Compass Therapeutics will post -0.36 earnings per share for the current year.

Institutional Trading of Compass Therapeutics

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its stake in Compass Therapeutics by 3,933.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after purchasing an additional 7,592 shares in the last quarter. Apollon Wealth Management LLC acquired a new stake in Compass Therapeutics in the 3rd quarter valued at about $35,000. CIBC Bancorp USA Inc. purchased a new position in shares of Compass Therapeutics in the 3rd quarter valued at about $37,000. Creative Planning purchased a new position in shares of Compass Therapeutics in the 2nd quarter valued at about $30,000. Finally, Victory Capital Management Inc. grew its position in shares of Compass Therapeutics by 20.6% during the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock worth $44,000 after buying an additional 2,164 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.